16:16 , Oct 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies identified a M. tuberculosis qcrB inhibitor that could help treat tuberculosis (TB). Screening of a compound library in cell-based assays identified a morpholino-thiophene-based compound that inhibited the growth of...
17:33 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Patient sample and mouse studies suggest fungal CYP51 inhibitors and other antifungal agents could enhance the efficacy of fecal microbiotal transplants to treat Clostridium difficile infection (CDI). In 16 CDI patients receiving fecal microbiota...
19:44 , Sep 14, 2018 |  BioCentury  |  Emerging Company Profile

Laekna’s jumping off place

Chinese biotech Laekna Therapeutics Shanghai Co. Ltd. is jump-starting its pipeline with a trio of clinical cancer compounds from Novartis AG. The safety of the lead candidate and its potential to synergize with the other...
19:32 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Acute lung injury Mouse studies suggest inhibiting ZMPSTE24 with Kaletra lopinavir/ritonavir could help treat acute lung injury (ALI). In a mouse model of ventilator-induced ALI, systemic ZMPSTE24 knockout decreased markers of injury and increased oxygenation...
17:59 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

FDA approves Biocodex's Diacomit for Dravet syndrome seizures

FDA approved Diacomit stiripentol from Laboratoires Biocodex (Gentilly, France) to treat seizures associated with Dravet syndrome in patients ages two and older who are taking clobazam. The anticonvulsant is a cytochrome P450 (p450) inhibitor. Laboratoires Biocodex,...
01:46 , Aug 17, 2018 |  BC Innovations  |  Targets & Mechanisms

Unsaturated remyelination

Enzymes downstream in cholesterol biosynthesis could provide new ways to stimulate remyelination that avoid the baggage of previously identified multiple sclerosis targets, according to a group at Case Western. The university is spinning out Convelo...
18:29 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

Strongbridge Biopharma plc (NASDAQ:SBBP) said Recorlev levoketoconazole met the primary and secondary endpoints in the Phase III SONICS trial to treat endogenous Cushing syndrome. On the 94-patient trial's primary endpoint, 30% of patients achieved normalization of...
17:57 , Jul 20, 2018 |  BC Week In Review  |  Company News

Takeda, Ovid expand TAK-935 collaboration with three new trials

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Ovid Therapeutics Inc. (NASDAQ:OVID) expanded their collaboration for TAK-935 (OV935) to include three new trials in pediatric populations, including in two additional rare epilepsy syndromes. The partners expect to...
16:53 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

FDA approves J&J's Symtuza for HIV-1 infection in adults

FDA approved Symtuza darunavir/cobicistat/emtricitabine/tenofovir alafenamide from Johnson & Johnson (NYSE:JNJ) to treat HIV-1 infection in adults who have not previously received antiretroviral therapy (ART) or who have HIV-1 RNA levels of less than 50 copies/mL...
21:36 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Cell culture and mouse studies identified an inhibitor of M. tuberculosis cytochrome bc1 that could help treat tuberculosis (TB). Screening of small molecule library in M. tuberculosis culture and chemical synthesis of analogs of...